Skip to main content
main-content

01.12.2017 | Letter to the Editor | Ausgabe 1/2017 Open Access

Health and Quality of Life Outcomes 1/2017

Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients

Zeitschrift:
Health and Quality of Life Outcomes > Ausgabe 1/2017
Autoren:
Massimo Breccia, Michele Baccarani, Gianantonio Rosti, Francesco Cottone, Laura Cannella, François Guilhot, Marco Vignetti, Fabio Efficace
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s12955-017-0788-4) contains supplementary material, which is available to authorized users.

Abstract

We investigated factors that physicians consider of most importance in the selection of second line tyrosine kinase inhibitors treatments (TKIs) in chronic myeloid leukemia patients (CML).
Zusatzmaterial
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

Health and Quality of Life Outcomes 1/2017 Zur Ausgabe